The pharmacological management of gastroesophageal reflux disease

Minerva Gastroenterologica e Dietologica

Volumn 50, Issue 3, 2004, Pages 227-237

  Lowe, R C ^a,b   Wolfe, M M ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastroesophageal reflux, therapy; Histamine R2 antagonists; Proton pump inhibitors

Indexed keywords

ALGINIC ACID; ALUMINUM HYDROXIDE; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGNESIUM; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEROTONIN 4 AGONIST; STOMACH SECRETION INHIBITOR;

AGITATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DYSPEPSIA; DYSTONIA; ESOPHAGUS MOTILITY; GALACTORRHEA; GASTROESOPHAGEAL REFLUX; GYNECOMASTIA; HEART ARRHYTHMIA; HEARTBURN; HUMAN; LIFESTYLE; MAINTENANCE THERAPY; META ANALYSIS; MOTOR DYSFUNCTION; PATHOGENESIS; PERIODICITY; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ANTACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HISTAMINE H2 ANTAGONISTS; HUMANS; LIFE STYLE; PROTON PUMPS;

EID: 10344221593     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Katz PO. Optimizing medical therapy for gastroesophageal reflux disease: state of the art. Rev Gastroenterol Disord 2003;3:59-69.
2. Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med 2003;70Suppl 5:S4-19.
3. Jones MP SS, Rabine JC. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1711-7.
4. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988;95:593-9.
5. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000;119:1439-46.
6. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci 1983;28:559-63.
7. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989;24:401-6.
8. Farup PG, Weberg R, Berstad A, Wetterhus S, Dahlberg O, Dybdahl J et al. Low-dose antacids versus 400 mg cimetidine twice daily for reflux oesophagitis. A comparative, placebo-controlled, multicentre study. Scand J Gastroenterol 1990;25:315-20.
9. Tytgat GN, Nio CY. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol 1987;1:791-807.
10. Castell D, Silvers D, Littlejohn T, Orr W, Napolitano J, Oleka N et al. Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group. Aliment Pharmacol Ther 1999;13:787-94.
11. Arvanitakis C, Nikopoulos A, Theoharidis A, Giannoulis E, Vagios I, Anthopoulou H et al. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease: a comparative randomized double-blind trial. Aliment Pharmacol Ther 1993;7:635-41.
12. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
13. Maton PN. Profile and assessment of GERD pharmacotherapy. Cleve Clin J Med 2003;70Suppl 5:S51-70.
14. McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984;79:165-72.
15. Guslandi M, Testoni PA, Passaretti S, Masci E, Ballarin E, Comin U et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983;30:96-8.
16. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:5-20.
17. Masci E, Testoni PA, Passaretti S, Guslandi M, Tittobello A. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985;11:687-92.
18. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990;19:683-712.
19. Sabesin SM, Berlin RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med 1991;151:2394-400.
20. Tytgat GN, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990;99:629-34.
21. Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol 1991;86:1735-42.
22. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118Suppl 1:S9-31.
23. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9Suppl 1:9-14.
24. Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995;9:145-51.
25. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995;9:25-31.
26. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999;13:1611-20.
27. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997:11Suppl B:66B-73B.
28. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001;23:998-1017.
29. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
30. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
31. Barrison AF, Jarboe LA, Weinberg BM, Nimmagadda K, Sullivan LM, Wolfe MM. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001;111:469-73.
32. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
33. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
34. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
35. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
36. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10.
37. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
38. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
39. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
40. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32.
41. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-6.
42. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-50.
43. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
44. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-8.
45. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
46. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
47. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98Suppl 3:S40-8.